Tolerability of fosamprenavir/ritonavir associated with zidovudine lamivudine used as postexposure prophylaxis for HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 3, 2008, Pages 334-336

  Burty, Christine ^a   Pavel, Simona ^b   Ghomari, Kamel ^b   Vermersch, Annie ^b   Christian, Bernard ^a   Pouaha, Jean ^a   Yazdanpanah, Yazdan ^b   May, Thierry ^a   Rabaud, Christian ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CENTRE HOSPITALIER DE TOURCOING   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR PLUS RITONAVIR; HEPATITIS B SURFACE ANTIBODY; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBAMIC ACID DERIVATIVE; ORGANOPHOSPHATE; SULFONAMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ASTHENIA; CLINICAL TRIAL; DIARRHEA; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LABORATORY TEST; LETTER; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL SPECIALIST; MULTICENTER STUDY; NAUSEA; NONHUMAN; OCCUPATION; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RASH; SEROLOGY; SEXUAL INTERCOURSE; TREATMENT OUTCOME; VIRUS TRANSMISSION; VOMITING; DRUG COMBINATION;

ADULT; ANTI-HIV AGENTS; CARBAMATES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; PHOSPHORIC ACID ESTERS; PROSPECTIVE STUDIES; RITONAVIR; SULFONAMIDES; ZIDOVUDINE;

EID: 58149163018     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31817c1f2d     Document Type: Letter

References (7)

1. Ministère des Affaires Sociales, du Travail et de la Solidarité, 2003. Circulaire DGS/DHOS/ DRT/DSS/SD6 A n° 2003-165 du 2 avril 2003 relative aux recommandations de mise en oeuvre d'un traitement antiretroviral après exposition au risque de transmission du VIH [in French]. Available at: http://www.sante.gouv. fr/adm/dagpb/bo/2003/03-23/ a0231611 .htm. Accessed April 2, 2003.
2. Pavel S, Burty C, Alcaraz I, et al. Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen. AIDS. 2007; 21:268-269.
3. Rabaud C, Bevilacqua S, Beguinot I, et al. CISIH Nancy Lorraine Champagne-Ardenne, France. Tolerability of post-exposure zidovudine + lamivudine + nelfinavir prophylaxis of HIV infection. Clin Infect Dis. 2001;32:1494-1495.
4. Rabaud C, Burty C, Grandidier M, et al. Tolerability of post-exposure prophylaxis of HIV infection with the combination of zidovudine/ lamivudine and lopinavir/ritonavir (Combivir®+ Kaletra®Clin Infect Dis. 2005;40:303-305.
5. Valle C, Prazuck T, Christian B, et al. Tolerability of post-exposure prophylaxis of HIV infection with the combination of zidovudine/ lamivudine + tenofovir [abstract TuPeB4647]. Paper presented at: XV International Conference on AIDS; July 13, 2004; Bangkok, Thailand.
6. Burty C, Christian B, Pouaha J, et al. Tolerability of post-exposure prophylaxis of HIV infection with the combination of lamivudine + tenofovir + atazanavir boosted with by ritonavir (LTA/r) [abstract 92/23O]. Paper presented at: 25th Reunion Interdisciplinaire de Chimiothérapie Anti Infectieuse; December 1, 2005; Paris, France.
7. Rabaud C, Burty C, Valle C, et al. Post-exposure prophylaxis of HIV infection: comparison of tolerability of 4 PEP regimens [abstract 905]. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver, CO.